Literature DB >> 12611789

Assertive community treatment across the Atlantic: comparison of model fidelity in the UK and USA.

Matthew Fiander1, Tom Burns, Gregory J McHugo, Robert E Drake.   

Abstract

BACKGROUND: The significant reductions in hospital admission demonstrated in US assertive community treatment (ACT) studies have not been replicated in the UK. Explanations cite poor UK 'model fidelity' and/or better UK standard care. No international model-fidelity comparisons exist. AIMS: To compare high-fidelity US ACT teams with a UK team.
METHOD: The UK 700's ACT team (n=97) was compared with high-fidelity US ACT teams (n=73) by using two measures: a forerunner of the Dartmouth Assertive Community Treatment schedule (to assess adherence to ACT principles) and 2-year prospective activity data.
RESULTS: The UK and US teams had similar high-fidelity scores. Although significant differences were found in the amount and type of activity, practice differences in areas central to ACT were not great.
CONCLUSIONS: The failure of UK ACT studies to demonstrate the outcome differences of early US studies cannot be attributed entirely to the lack of ACT fidelity.

Mesh:

Year:  2003        PMID: 12611789     DOI: 10.1192/bjp.182.3.248

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  19 in total

1.  A randomized-controlled trial of intensive case management emphasizing the recovery model among patients with severe and enduring mental illness.

Authors:  S O'Brien; J McFarland; B Kealy; A Pullela; J Saunders; W Cullen; D Meagher
Journal:  Ir J Med Sci       Date:  2012-01-05       Impact factor: 1.568

Review 2.  ACT and recovery: integrating evidence-based practice and recovery orientation on assertive community treatment teams.

Authors:  Michelle P Salyers; Sam Tsemberis
Journal:  Community Ment Health J       Date:  2007-05-21

3.  Fidelity and recovery-orientation in assertive community treatment.

Authors:  Sean A Kidd; Lindsey George; Maria O'Connell; John Sylvestre; Helen Kirkpatrick; Gina Browne; Lehana Thabane
Journal:  Community Ment Health J       Date:  2009-12-24

4.  Integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders.

Authors:  Daniel William Chandler; Gary Spicer
Journal:  Community Ment Health J       Date:  2006-08-24

5.  Implementation of assertive community treatment in Australia: model fidelity, patient characteristics and staff experiences.

Authors:  Carol Harvey; Helen Killaspy; Salvatore Martino; Sonia Johnson
Journal:  Community Ment Health J       Date:  2011-11-17

6.  Implementing evidence-based psychotherapies in settings serving older adults: challenges and solutions.

Authors:  Patricia A Arean; Patrick J Raue; Jo Anne Sirey; Mark Snowden
Journal:  Psychiatr Serv       Date:  2012-06       Impact factor: 3.084

7.  The role of a clinical director in developing an innovative assertive community treatment team targeting ethno-racial minority patients.

Authors:  Samuel Law
Journal:  Psychiatr Q       Date:  2007-09

8.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

Review 9.  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Authors:  Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

10.  Assertive community treatment for elderly people with severe mental illness.

Authors:  Jolanda Stobbe; Niels C L Mulder; Bert-Jan Roosenschoon; Marja Depla; Hans Kroon
Journal:  BMC Psychiatry       Date:  2010-10-19       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.